Overcoming platinum resistance through the use of a copper-lowering agent

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1221-1225

  Fu, Siqing ^a   Naing, Aung ^a   Fu, Caroline ^b   Kuo, Macustien ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CERULOPLASMIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; INTERFERON; LETROZOLE; PACLITAXEL; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TEMSIROLIMUS; TOPOTECAN; TRIENTINE; VANDETANIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT OBSTRUCTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; COPPER BLOOD LEVEL; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; HUMAN; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; PILOT STUDY; PRIORITY JOURNAL; SIDEROBLASTIC ANEMIA; THROMBOCYTOPENIA; VAGINA BLEEDING;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CATION TRANSPORT PROTEINS; CHELATING AGENTS; COPPER; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PILOT PROJECTS; TRIENTINE;

EID: 84862570268     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0864     Document Type: Article

References (21)

1. Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 2010;19: 1339-54.
2. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011;117: 1661-9.
3. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007;26: 71-83. (Pubitemid 46452185)
4. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010;77:887-94.
5. Lu J. Triethylenetetramine pharmacology and its clinical applications. Mol Cancer Ther 2010;9:2458-67.
6. ClinicalTrials.gov. Bethesda (MD): U.S. NIH. Available from: http:// clinicaltrials.gov/ct2/show/NCT01178112. Accessed 2012 Mar.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
8. National Cancer Institute. Bethesda (MD): U.S. NCI. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). Available from: http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ctc.htm#ctc-40. Accessed 2012 Mar 24.
9. Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, et al. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol 2008;74:697-704.
10. Liang ZD, Stockton D, Savaraj N, Tien Kuo M. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol 2009;76:843-53.
11. Chan A, Wong F, Arumanayagam M. Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas. Ann Clin Biochem 1993;30:545-9. (Pubitemid 23344608)
12. Lee YY, Choi CH, Do IG, Song SY, Lee W, Park HS, et al. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol 2011;122:361-5.
13. Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006;71:168-75.
14. Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, et al. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 2008;14: 7526-34.
15. Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008;86:383-9, discussion 390.
16. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-72. (Pubitemid 36554589)
17. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1-10. (Pubitemid 30064969)
18. Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD, et al. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 2009;27: 159-65.
19. Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzalez de Leon C, Fishman A, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995;13:1584-8.
20. Leitao MM Jr, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, et al. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 2003;91:123-9. (Pubitemid 37188601)
21. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006;5:952-61. (Pubitemid 43724595)